Program

 UPDATE ON HIV AND SARS-CoV-2: TWO PANDEMIC INFECTIONS
SARS-CoV-2 HOT TOPICS
Chaired by Sarah Gerlo and Wojciech Witkowski
09:00-09.05Welcome and Introduction
Linos Vandekerckhove, Ghent University and Ghent University Hospital, Ghent, Belgium
09:05-0-30From HIV to SARS-CoV-2, from one pandemia to another
Nathan Clumeck, Saint-Pierre University Hospital-ULB , Brussels, Belgium
09.30-09.55Covid-19 diseases and opportunities for immunotherapy
Bart Lambrecht, Ghent University, Ghent, Belgium
09.55-10.20Vaccine development efforts for SARS-CoV-2 at J&J
Hanneke Schuitemaker, Janssen Pharmaceuticals, Leiden, Netherlands
10.20-10.45Break
SARS-CoV-2 THERAPEUTIC APPROACHES AND SOCIETAL IMPACT
Chaired by Steven Callens and Kevin Ariën
10.45-11.10Animal models for SARS-CoV-2 compound and vaccine development screening
Johan Neyts, KU Leuven, Leuven, Belgium
11.10-11.35Nanobodies to treat SARS-CoV-2 moving towards clinical trials
Xavier Saelens, VIB and Ghent University Ghent, Belgium
11.35-12.00Balance between COVID-19 and societal impact
Lieven Annemans, Ghent University and Brussels University (VUB), Ghent, Belgium
12.00-13.00Break/Satellite Symposium
1. “Remdesivir for the treatment of COVID-19” : Dr. Tomas Cihlar (Vice President Discovery Virology, Gilead Sciences)
2. “Gilead’s HIV Cure Strategy”: Dr. Wade Blair (Executive Director Discovery Virology, Gilead Sciences
UNMASKING THE HIV VIRAL RESERVOIR
Chaired by Linos Vandekerckhove and Marion Pardons
13.00-13.25Distinct viral reservoirs in individuals with spontaneous control of HIV-1
Mathias Lichterfeld, Harvard Medical School, Boston, US
13.25-13.50How to link clonal proliferation, intact viral sequences and HIV-1 viral rebound
Basiel Cole, Ghent University, Ghent, Belgium
13.50-14.15Implementing HIV-1 intact proviral assays in clinical trials and clinical practice
Robert Siliciano, Johns Hopkins University, Maryland, US
14.15-14.30Break
IMMUNE STRATEGIES FOR SARS-CoV-2 AND HIV
Chaired by Guido Vanham and Gilles Darcis
14.30-14.55TCR adapted therapies to cure HIV-1
Lucy Dorrell, University of Oxford, Oxford, UK
14.55-15.20Immunocorrelates of SARS-CoV-2 protection
Susan Ribeiro, Case Western Reserve University, Cleveland, US
15.20-15.45Current status on HIV-1 Cure clinical trials
Linos Vandekerckhove, Ghent University and Ghent University Hospital, Ghent, Belgium
15.45-16.00Break
16.00-16.15Closing and voting results
Linos Vandekerckhove, Ghent University and Ghent University Hospital, Ghent, Belgium